Denmark is the homeland of probiotics. Its dairy culture and rigorous food science gave the world Lactobacillus, and its pharmacy shelves have long been dominated by Nordic brands. However, a Korean company now holds the number-two spot in that very market — with roughly 46.6% share — having beaten out local incumbents on their own turf. That detail alone tells you something is happening with Korean probiotics that deserves attention.

That company is Cell Biotech, and its premium line DUOLAC has just secured an exclusive listing on Shinsegae Duty Free’s online platform. For investors tracking the convergence of Korean retail and life sciences, this partnership is worth a close look.

Thirty Years of Quiet Science Behind Korean Probiotics

Cell Biotech is not a startup riding a wellness wave. Founded over three decades ago, it is a first-generation Korean biotech that set out to domesticate probiotic strains at a time when the country imported virtually all of them. Its proprietary CBT strains were isolated from Korean gut microbiomes — specifically from people who consume the country’s signature high-spice diet of garlic, chili, and fermented vegetables. In other words, these strains were engineered for resilience.

The company’s core technology, called Dual Coating, encases live bacteria in a protective shell that survives stomach acid and bile. Human trials show survival rates up to 221 times higher than uncoated strains. That is not a marketing claim — it is a measurable clinical outcome, and it explains why DUOLAC now ships to 55 countries.

Furthermore, Cell Biotech recorded approximately ₩25.9 billion (roughly $19 million) in exports in 2023 alone — representing over 44% of Korea’s total probiotic export value of ₩58.4 billion. It has held the top export position for 12 consecutive years. In Singapore and Indonesia, DUOLAC ranks first in its category. The Denmark story is impressive precisely because it is the hardest market to crack.

Shinsegae’s Strategic Bet on Korean Probiotics

Shinsegae Duty Free — part of the Shinsegae Group conglomerate, one of Korea’s largest retail empires — is not simply adding a health supplement to its catalogue. The company is repositioning its online duty-free store as what it calls an “experiential retail touchpoint” for global consumers interested in Korean healthcare.

Duty-free retail in Korea operates in a specific context worth explaining. Foreign tourists and departing travelers shop at duty-free stores — both physical and online — and can pick up goods before or after their flight. The online channel, in particular, has become a powerful vehicle for reaching health-conscious visitors who research products before they arrive in the country.

The initial DUOLAC lineup includes ten products. The range runs from DUO D-DROPS for infants to DUOLAC Gold capsules for adults. As a result, families traveling together can stock up across age groups in a single transaction. Shinsegae is clearly testing whether the trust built by K-beauty — which turned Korean skincare into a global phenomenon — can be extended to K-wellness. The bet is that it can, and the data from Cell Biotech’s international track record provides reasonable backing.

Meanwhile, the global probiotics market is projected to reach approximately $165 billion by 2034, growing at an 8.5% compound annual rate. For any brand with a credible clinical story and proven export history, that trajectory represents a substantial runway.

DUOLAC Stop: A Product Built for the Journey

In particular, Shinsegae is spotlighting one product as the hero SKU of this launch: DUOLAC Stop, formulated specifically for travelers. Gut disruption — commonly called “traveler’s diarrhea” — affects a large share of international tourists and is one of the most searched health concerns among people planning overseas trips.

DUOLAC Stop contains Prolac-T, a natural antimicrobial compound shown to inhibit harmful bacteria including salmonella. Therefore, it targets a genuine pain point rather than a vague wellness aspiration. The product already has organic momentum: it went viral on Chomad, a Korean travel-focused YouTube channel with a substantial following, where it was recommended as a travel essential. Word-of-mouth on social platforms like this has become a primary discovery channel for health products in Korea.

Gut health is no longer a niche concern. It sits at the intersection of immunity, mental health, and digestive wellness — three categories that have all seen accelerated consumer interest since the pandemic.

Beyond Supplements: A Biotech Company in Disguise

What makes Cell Biotech more interesting than a typical nutraceutical brand is its pipeline. The company is advancing PP-P8, a microbiome-based drug candidate targeting colorectal cancer, through clinical trials. In other words, Cell Biotech is quietly transitioning from a functional food company into a biopharmaceutical player — using the same proprietary strains that built DUOLAC’s commercial success.

Cell Biotech’s CEO Jung Myung-jun has stated that the company intends to “continue securing leadership in the global probiotic market, backed by the strength of K-probiotics and our proprietary technology.” That ambition, combined with a clinical-stage oncology asset, places the company in a category that few consumer health brands occupy.

For investors, the Shinsegae partnership therefore functions as both a distribution deal and a brand-building exercise. It gives DUOLAC a premium retail environment frequented by international travelers — precisely the audience most likely to carry a product home and recommend it abroad. By contrast with a conventional wholesale arrangement, duty-free placement carries an implicit quality endorsement in the minds of many Asian consumers.

K-Wellness Is the Next Export Story

K-beauty took years to build its global reputation. K-food followed. K-wellness, however, has the advantage of arriving with clinical infrastructure already in place. Korea’s wellness tourism sector is expanding rapidly, and inbound foreign visitors are increasingly purchasing inner beauty and supplement products alongside cosmetics.

The Shinsegae–DUOLAC deal is a small but telling signal. It shows that Korean retail is no longer waiting for Western validation. Instead, it is using its own infrastructure — duty-free platforms, social commerce, wellness tourism — to take Korean gut health products directly to a global audience. Furthermore, the promotional campaign running alongside the launch, which offers free DUOLAC products with purchases above set thresholds, is designed to convert first-time buyers into repeat customers.

A Shinsegae spokesperson summed it up directly: “Our global shopping platform is a channel where customers can directly experience the competitiveness of Korean gut health products.” That framing — experience, not just purchase — reflects a broader shift in how Korean brands are thinking about international growth. The gut, it turns out, may be the next frontier for Korea’s export ambitions.